World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
28043
World Ranking
16500
National Ranking
859

Overview

Michael Heuser is affiliated with Hannover Medical School in Germany and has a substantial research portfolio primarily in the medical sciences. Their work focuses predominantly on hematology and molecular biology, with significant contributions spanning acute myeloid leukemia and related hematologic disorders.

Their main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Within these, subfields of research concentrate on hematology, molecular biology, genetics, public health, environmental and occupational health, and oncology.

Major topics covered in their research encompass:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Cancer Genomics and Diagnostics
  • Protein Degradation and Inhibitors
  • Multiple Myeloma Research and Treatments

Michael Heuser has published extensively in various scientific journals. Frequent publication venues include:

  • Blood
  • HemaSphere
  • Leukemia
  • Blood Advances
  • Clinical Lymphoma Myeloma & Leukemia

Among recent papers associated with or authored by Michael Heuser are:

  • 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), 2022, European Heart Journal
  • Molecular International Prognostic Scoring System for Myelodysplastic Syndromes, 2022, NEJM Evidence
  • 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party, 2021, Blood
  • Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes, 2020, Nature Medicine
  • 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS), 2022, European Heart Journal - Cardiovascular Imaging

Michael Heuser collaborates regularly with several researchers who frequently co-author with them, including:

  • Felicitas Thol
  • Hartmut Döhner
  • Arnold Ganser
  • Konstanze Döhner
  • Walter Fiedler

Best Publications

  • Genomic Classification and Prognosis in Acute Myeloid Leukemia

    Elli Papaemmanuil;Moritz Gerstung;Lars Bullinger;Verena I Gaidzik

  • Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

    Gerrit J. Schuurhuis;Michael Heuser;Sylvie Freeman;Marie Christine Béne

  • Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

    Felicitas Thol;Sofia Kade;Carola Schlarmann;Patrick Löffeld

  • Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia

    Felicitas Thol;Frederik Damm;Andrea Lüdeking;Claudia Winschel

  • Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Elsa Bernard;Yasuhito Nannya;Robert P. Hasserjian;Sean M. Devlin

  • 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

    Michael Heuser;Sylvie D Freeman;Gert J Ossenkoppele;Francesco Buccisano

  • Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Jorge E. Cortes;Florian H. Heidel;Andrzej Hellmann;Walter Fiedler

  • High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.

    Michael Heuser;Gernot Beutel;Juergen Krauter;Konstanze Döhner

  • Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

    Felicitas Thol;Inna Friesen;Frederik Damm;Haiyang Yun

  • How I treat refractory and early relapsed acute myeloid leukemia.

    Felicitas Thol;Richard Friedrich Schlenk;Michael Heuser;Arnold Ganser

  • Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

    Katharina Wagner;Frederik Damm;Gudrun Göhring;Kerstin Görlich

  • Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

    Felicitas Thol;Razif Gabdoulline;Alessandro Liebich;Piroska Klement

  • RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

    V I Gaidzik;V Teleanu;E Papaemmanuil;D Weber

  • Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection.

    Sarina Ravens;Christian Schultze-Florey;Solaiman Raha;Inga Sandrock

  • Precision oncology for acute myeloid leukemia using a knowledge bank approach

    Moritz Gerstung;Moritz Gerstung;Elli Papaemmanuil;Elli Papaemmanuil;Inigo Martincorena;Lars Bullinger

  • Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

    Richard F. Schlenk;Richard F. Schlenk;Daniela Weber;Walter Fiedler;Helmut R. Salih

  • Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

    Anuhar Chaturvedi;Michelle Maria Araujo Cruz;Nidhi Jyotsana;Amit Sharma

  • IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

    Felicitas Thol;Eva M. Weissinger;Jürgen Krauter;Katharina Wagner

  • Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

    Felicitas Thol;Frederik Damm;Katharina Wagner;Gudrun Göhring

  • TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

    Detlef Haase;Kristen E Stevenson;Donna Neuberg;Jaroslaw P Maciejewski

Frequent Co-Authors

Arnold Ganser
Arnold Ganser Hannover Medical School
Konstanze Döhner
Konstanze Döhner University of Ulm
Hartmut Döhner
Hartmut Döhner University of Ulm
Richard F. Schlenk
Richard F. Schlenk University Hospital Heidelberg
Gudrun Göhring
Gudrun Göhring Hannover Medical School
Brigitte Schlegelberger
Brigitte Schlegelberger Hannover Medical School
Lars Bullinger
Lars Bullinger Charité - University Medicine Berlin
Michael Lübbert
Michael Lübbert University of Freiburg
Jorge E. Cortes
Jorge E. Cortes Augusta University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in a medical career but not pursuing a traditional MD, there are numerous accessible online pathways. Options such as online medical coding classes with financial aid can help learners launch a healthcare career without clinical requirements. These programs offer affordable and flexible entry into essential health services roles.

Aspiring nurses have opportunities as well; some lpn school without teas test options let you start nursing education without entrance exams, making the process less daunting.

Professionals seeking growth might pursue accelerated healthcare programs. These let you move quickly into management and administrative roles, addressing the ongoing need for healthcare leaders.

Finally, registered nurses can advance their careers and increase earning potential through adn to msn bridge programs. These flexible online options streamline the journey to advanced practice or education tracks.

Best Scientists Citing Michael Heuser

Trending Scientists

Recently Published Articles